A new probe may aid in complete removal of cancer tissue during surgery

November 30, 2016

Bottom Line: An optical fiber probe can distinguish cancer tissue and normal tissue at the margins of a tumor being excised, in real time, by detecting the difference in pH between the two types of tissue. This has the potential to help surgeons avoid removing too much healthy tissue during surgery and also avoid performing additional surgeries later to remove any cancer tissue left behind.

Journal in Which the Study was Published: Cancer Research, a journal of the American Association for Cancer Research.

Authors: Erik P. Schartner, PhD, a postdoctoral researcher at the School of Physical Sciences and the ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP) at The University of Adelaide in Australia, working in collaboration with the Breast, Endocrine & Surgical Oncology Unit at the Royal Adelaide Hospital.

Background: A major issue with current surgical techniques to resect cancer is the lack of a reliable method to identify the tissue type during surgery; therefore the surgical procedures rely extensively on the experience and judgement of the surgeon to decide on how much tissue to remove around the tumor margins, Schartner said. Because of this, surgeons often perform what is called cavity shaving, which can result in the removal of excessive healthy tissue. On the other hand, many patients do not have the entire tumor removed during the initial surgery, and will need a follow-up surgery to remove residual cancer tissue.

"This is quite traumatic to the patient, and has been shown to have long-term detrimental effects on the patient's outcome," he added.

How the Study Was Conducted: Schartner and team designed an optical fiber probe that can detect cancer cells during surgery based on the principle that cancer and normal cells have different pH, which is a measure of the acidity or basicity (alkalinity) of a substance. Tumor cells are typically more acidic than normal cells, Schartner noted.

When the probe is applied to the tissue, the pH indicator embedded in the polymer layer at the tip of the fiber optic probe changes the color of the light it emits depending on the pH of the area that it is placed in. The probe is connected to a light source, which emits fluorescence that can be detected with a miniature spectrometer on the other end of the probe, Schartner explained.

The researchers tested their probe on four mastectomy specimens, one specimen of axillary clearance from a patient with recurrent breast cancer, and three specimens of metastatic melanoma.

Results: After multiple measurements of the margins of these samples, the researchers found that this pH method was able to differentiate tumor and normal areas with 88 percent sensitivity and 90 percent selectivity. Pathological evaluation of these samples to determine tumor and normal areas was used as reference.

In order to avoid interference in measurements from autofluorescence, a phenomenon in which the cells emit light by themselves, the researchers employed a "lift and measure" technique. To do this, the probe is first made to touch the tissue, but the fluorescence is measured after the probe is lifted from the tissue surface, at which point the probe retains the initial measurement but is devoid of the interference from the light emitted by the tissue.

Author Comment: "We have designed and tested a fiber-tip pH probe that has very high sensitivity for differentiating between healthy and cancerous tissue with an extremely simple experimental setup that can already be used in a fully portable configuration," said Schartner.

"Because it is cost-effective to do measurements in this manner compared to many other medical technologies, we see a clear scope for broader use of this technology in operating theaters," he added.

"Eliminating the autofluorescence background by the 'lift and measure' method we used overcomes one of the main limitations that usually restricts the performance of fluorescence-sensing methods," Schartner noted. With their probe, the initial signal was stable up to 10 minutes after lifting.

"We are currently in the process of obtaining more excised tissue samples to increase our database, with the view of moving this towards clinical studies in the near future," Schartner said. "We are pushing strongly for commercial development of this probe with industry partners."

Limitations: Limitations of the study include the small sample size and further improvements needed to enhance the probe's specificity.
-end-
Funding & Disclosures: The study was supported by the National Breast Cancer Foundation of Australia and the Australian Research Council.

Follow us: Cancer Research Catalyst http://blog.aacr.org; Twitter @AACR; and Facebook http://www.facebook.com/aacr.org

For AACR information, visit Fast Facts

About the American Association for Cancer Research

Founded in 1907, the American Association for Cancer Research (AACR) is the world's first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 37,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 108 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with nearly 19,500 attendees. In addition, the AACR publishes eight prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit http://www.AACR.org.

To interview Erik Schartner, contact Julia Gunther at julia.gunther@aacr.org or 215-446-6896.

American Association for Cancer Research

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.